AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06318975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated and Targeted Text Messages
Description: All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
Study NCT06436469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-Based Stress Reduction (MBSR) Program
Description: The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
Study NCT05784363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
Study NCT05784363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Study NCT06568770 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK
Description: With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected
Study NCT06568770 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PERICAPSULAR NERVE BLOCK
Description: an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected.
Study NCT05682352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 158968
Description: IV infusion or SC injection
Study NCT05682352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion or SC injection
Study NCT05682352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 158968
Description: SC injection
Study NCT05682352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection
Study NCT04965896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control meal
Description: Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
Study NCT04965896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nut meal
Description: Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
Study NCT04532489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FNP-59
Description: FNP-59, a radiotracer, is administered for PET/CT scans.
Study NCT05324254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
Study NCT04992897 — intervention group
Intervention type: DEVICE
Intervention: Remote Electrical Neuromodulation (REN)
Description: Acute migraine treament
Study NCT05409664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity adoption
Description: webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
Study NCT05409664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring
Description: Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
Study NCT06543095 — intervention group
Intervention type: OTHER
Intervention: Pain level
Description: Post-operative pain levels of the patients with detected using VAS score.
Study NCT04930536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib capsule
Description: The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
Study NCT05620706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC3 CAR-T cells
Description: patients treated with GPC3 CAR-T cells
Study NCT04958733 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Absence of autologous bone grafting
Description: Donor sites will be left unfilled
Study NCT05762666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nociception level index monitor
Description: The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
Study NCT06368492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
Study NCT06368492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis script
Description: All participants will receive a brief hypnotic induction aimed at producing analgesia before the second administration of CPT
Study NCT05602220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain training
Description: Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
Study NCT05602220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced breathing
Description: After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
Study NCT05589246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: regional analgesia with cryolesia
Description: The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
Study NCT04827095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Support and Education Program 1
Description: The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
Study NCT04827095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Support and Education Program 2
Description: The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
Study NCT05270512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
Study NCT04806958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PulsePoint notification
Description: The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator.
Study NCT05043220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG and PROM
Description: description will follow
Study NCT05692739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: see arm description
Study NCT05692739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: see arm description
Study NCT05692739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: see arm description
Study NCT06222879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080; SHR-A1811
Description: Participants will receive HRS-8080 and SHR-A1811
Study NCT06222879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080; SHR-A2009
Description: Participants will receive HRS-8080 and SHR-A2009
Study NCT06222879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009; SHR-1316
Description: Participants will receive SHR-A2009 and SHR-1316
Study NCT05744219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Active drug
Study NCT05744219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06150872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DurVena Photochemical Tissue Passivation
Description: Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
Study NCT05290805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECMO flow rate reduction
Description: ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
Study NCT06333041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
Study NCT06333041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
Study NCT05680727 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
Study NCT05678101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation (TENS)
Description: Chattanooga Physio TENS (DJO Global, Vista, CA)
Study NCT05678101 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation (TENS)
Description: Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
Study NCT05819645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid intake not as per standard guidlines
Description: The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
Study NCT05819645 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fluid intake not as per standard guidlines
Description: The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
Study NCT04730973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
Study NCT04730973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lipid-lowering therapy (LLT)
Description: lipid-lowering therapy (LLT)
Study NCT04730973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lipid-lowering therapy (LLT)
Description: lipid-lowering therapy (LLT)
Study NCT05740839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT Exercise Program
Description: Exercise program with stationary bike via the Zoom platform.
Study NCT05740839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Usual Activities
Study NCT06232733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyles Project e-intervention
Description: Virtual lifestyle behaviour change support.
Study NCT06232733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Project e-intervention
Description: Virtual lifestyle behaviour change support.
Study NCT06364826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, bevacizumab, gemcitabine
Description: This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
Study NCT06364826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT
Study NCT06075602 — intervention group
Intervention type: DEVICE
Intervention: Impact of current PCI techniques/ devices in complex coronary artery lesions
Description: To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
Study NCT05331378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses
Description: A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
Study NCT05331378 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single vision lenses
Description: A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
Study NCT04977804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The interventions are a form or exercise, specifically resistance exercise.
Study NCT04977804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric plus blood-flow restriction
Description: Eccentric plus blood-flow restriction
Study NCT05383131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: Mulltiple doses of HEC585 for up to 10 days
Study NCT06070701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial Parasternal Block (SIPB)
Description: Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
Study NCT06070701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (ESPB)
Description: Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
Study NCT06070701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: During general anesthesia, fentanyl is administered according to NOL monitoring.
Study NCT06070701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: During general anesthesia, fentanyl is administered according to NOL monitoring.
Study NCT06070701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
Study NCT06070701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
Study NCT06553131 — intervention group
Intervention type: DEVICE
Intervention: Neuromuscular Transmission Monitoring
Description: A neuromuscular transmission module connected to electrodes applied to the skin and positioned to provide stimulation of a single nerve and monitor the muscular response to nerve stimulation
Study NCT04014296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: 16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
Study NCT04014296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
Study NCT06080503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LT-SABR
Description: 42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
Study NCT06080503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)